NPS 2390 – 5 mg

Brand:
Cayman
CAS:
226878-01-9
Storage:
-20
UN-No:
Non-Hazardous - /

Metabotropic glutamate receptors (mGluRs), mediate excitatory synaptic transmission in the central nervous system. Potent and selective antagonists of the type I mGluRs (mGluR1 and mGluR5) are of interest as novel therapeutics for the treatment of various CNS disorders, such as pain, epilepsy, and stroke.{21993,21995} NPS 2390 is a first generation quinoxaline derivative that acts as a noncompetitive antagonist of mGluR1 and mGluR5 with IC50 values equal to 5.2 and 82 nM, respectively).{21992} At concentrations up to 30 μM, NPS 2390 does not affect mGluR2 or mGluR8 or a standard collection of 37 additional receptors, ion channels, and enzymes.{21992} At a dose of 10 mg/kg, NPS 2390 displaced the specifically bound mGlu1R-selective antagonist, [3H]R214127, in rat cerebellum.{21994}  

 

Available on backorder

SKU: 11989 - 5 mg Category:

Description

A first generation quinoxaline derivative that acts as a noncompetitive antagonist of mGluR1 and mGluR5 (IC50s = 5.2 and 82 nM, respectively)


Formal name: N-tricyclo[3.3.1.13,7]dec-1-yl-2-quinoxalinecarboxamide

Synonyms: 

Molecular weight: 307.4

CAS: 226878-01-9

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Neuroscience